Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 139 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

139 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 139 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

139 programs

Clinical programs

Page 2 of 3

  1. Drug use prevention intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Behavior

    phase 3 other completed

    1 trial

  2. Emixustat

    BRIGHT MINDS BIOSCIENCES INC.

    Stargardt Disease

    phase 3 small molecule completed

    1 trial

  3. Empowered Relief On-Demand

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Pain

    phase 3 other completed

    1 trial

  4. Enhanced care

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Addiction

    phase 3 other completed

    1 trial

  5. Erythromycin

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 small molecule completed

    1 trial

  6. Escitalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  7. Extended Release Buprenorphine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorder

    phase 3 small molecule completed

    1 trial

  8. Extended Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule completed

    1 trial

  9. Extended treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 small molecule completed

    1 trial

  10. Fluoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  11. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Dependence

    phase 3 small molecule completed

    1 trial

  12. Gabapentin 300mg

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol Drinking

    phase 3 small molecule completed

    1 trial

  13. H. pylori vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  14. HealthWise South Africa curriculum

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 other completed

    1 trial

  15. Hypnotic Medication Open-Label Taper

    BRIGHT MINDS BIOSCIENCES INC.

    Hypnotic Dependence Among Those With Insomnia

    phase 3 other active

    1 trial

  16. Internet-based smoking treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 3 other completed

    1 trial

  17. KLWS-V502-04

    BRIGHT MINDS BIOSCIENCES INC.

    Human Papillomavirus Infection

    phase 3 mab active

    1 trial

  18. Learning Session

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 3 other completed

    1 trial

  19. Live-Attenuated influenza Vaccine(LAIV)

    BRIGHT MINDS BIOSCIENCES INC.

    Influenza

    phase 3 mab completed

    1 trial

  20. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule completed

    3 trials

  21. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Addiction

    phase 3 small molecule completed

    1 trial

  22. Lofexidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Withdrawal

    phase 3 small molecule completed

    1 trial

  23. Lofexidine HCl

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 3 small molecule completed

    1 trial

  24. Losartan

    BRIGHT MINDS BIOSCIENCES INC.

    Glomerulonephritis, IGA

    phase 3 small molecule completed

    1 trial

  25. MORE

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 3 other active

    1 trial

  26. MORE and MI and NRT

    BRIGHT MINDS BIOSCIENCES INC.

    Polysubstance Abuse

    phase 3 other active

    1 trial

  27. Marijuana Check-Ins

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 3 other completed

    1 trial

  28. Methadone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 3 small molecule terminated

    2 trials

  29. Methadone (100% dose)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 3 small molecule active

    1 trial

  30. Methadone Treatment-As-Usual

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 3 small molecule active

    1 trial

  31. Motivational interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  32. Moxifloxacin

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis, Pulmonary, Drug Sensitive

    phase 3 small molecule completed

    1 trial

  33. N-Acetylcysteine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    2 trials

  34. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 3 small molecule active

    1 trial

  35. Nabilone

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 3 small molecule completed

    1 trial

  36. Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 3 small molecule completed

    1 trial

  37. Nicotine Patch

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 3 small molecule completed

    2 trials

  38. Nicotine polacrilex, Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 3 small molecule completed

    1 trial

  39. Omalizumab (Xolair)

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Urticaria

    phase 3 small molecule completed

    1 trial

  40. On-site bundled rapid HIV/HCV testing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-related Disorders

    phase 3 other completed

    1 trial

  41. One4All

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 3 other completed

    1 trial

  42. Oral micronized progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 3 small molecule completed

    1 trial

  43. Oxygen (15-O) Water

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 3 small molecule completed

    1 trial

  44. Paclitaxel dosing according to SmPC

    BRIGHT MINDS BIOSCIENCES INC.

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  45. Peer HIV Education Program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 3 other completed

    1 trial

  46. Peer Mentoring Intervention for HCV-Infected IDUs

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis C

    phase 3 other completed

    1 trial

  47. Pergolide

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 3 small molecule completed

    1 trial

  48. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

139 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.